technology

And still they keep coming – here’s the fifth instalment of our series on the fascinating ASX cohort of medical device developers. As always, don’t let the impressive sexiness of the technology persuade you on its own that these stocks are headed for the stars. In each of the three cases presented here, previous investors…

Initial Public Offering 101 If you have been reading any financial media, or even social media, at all throughout 2020, you likely get the feeling that the IPO market has been growing like crazy. This is something my colleague, Ishan Dan, has addressed in his article this week, called IPO market review – who delivered…

Neobank Douugh (ASX: DOU) shares are up 30% at the time of writing, and up a whopping 1100% after a successful backdoor listing on the ASX at 3c. Neobanks (or digital banks) are simply new app-based banks. No branches, no cash, and interaction entirely through a smartphone app. Although dubbed a neobank, Douugh is so…

Hamish Douglass, the CIO of Magellan Financial Group, who oversees the largest Australian-owned global funds manager and is the current darling of the wholesale and retail investor sectors, is relatively sanguine about the possible market impact of the US election, but a bit more worried about COVID-19. Douglass, also Magellan’s co-founder, with Chris Mackay, chairman…

One of the great investment success stories of the last 25 years has been the exchange-traded fund (ETF), which got under way in the early 1990s as a vehicle offering access, in one listed stock, to the entire stock market through tracking an index. Gone were the worries of paying “active” management fees and failing…

Here’s the fourth instalment of our series on the fascinating ASX cohort of medical device developers. ImpediMed (IPD, 8.1 cents)Market capitalisation: $83.8 millionThree-year total return: -52.7% a yearAnalysts’ consensus target price: 14 cents (Thomson Reuters) You would not know it from the share price performance over the last few years, but Brisbane-based ImpediMed has put…

Shares in consumer lending company Plenti (ASX: PLT) look to have stabilised, having tumbled 25% from the initial IPO price of $1.66. At the time of writing the share price sits at $1.28. Given the haircut applied to the stock in the secondary market, is Plenti worth a punt? Firstly, what does Plenti do? Formerly…